Ixemple A Phase Iii Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel Or Doxorubicin Administered Every 21 Days In Women with Advanced Endometrial Cancer Who Have Previously Been Treated with Chemotherapy Trademark Details

This mark is dead with a status of Misassigned Serial Number. The last case file activity for this mark occured 14 years ago on Friday, June 19, 2009, according to the United State Patent & Trademark Office
Word Mark Ixemple a Phase III Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel or Doxorubicin Administered Every 21 Days in Women with Advanced Endometrial Cancer Who Have Previously Been Treated with Chemotherapy
Status Dead 622 — Misassigned Serial Number

Current Owner

Bristol-Myers Squibb Company of New York, NY

View all trademarks for Bristol-Myers Squibb Company
Other Trademarks for Bristol-Myers Squibb Company
Serial Number 77760937
Status Date Friday, June 19, 2009
Filing Date Friday, June 19, 2009
Attorney Nadine P. Flynn

Correspondent

NADINE P. FLYNN
BRISTOL-MYERS SQUIBB COMPANY
345 PARK AVENUE
TRADEMARK DEPARTMENT
NEW YORK, NY 10154

Case File Statements

Goods & Services Medical and scientific research, namely, conducting clinical trials and clinical studies relating to pharmaceutical preparations for human use

Classifications

International Class Codes
042 — Class 42 includes mainly services provided by persons, individually or collectively, in relation to the theoretical and practical aspects of complex fields of activities; such services are provided by members of professions such as chemists, physicists, engineers, computer programmers, etc.
U.S. Class Codes 100, 101
Status 6 — Active
Status Date Friday, June 19, 2009
Primary Code 042

You must be signed in to print.

Once signed in, look for the PDF button.